FOXO4-DRI

Mechanism

A peptide that selectively kills senescent "zombie" cells — old, damaged cells that refuse to die and instead secrete inflammatory chemicals that age your tissues. By clearing these cells, it can restore tissue function. In old mice, it restored fitness, fur density, and kidney function. It's the first peptide-based senolytic.

Effects

MUSCULOSKELETAL: In aged mice, cleared senescent cells from muscle tissue, improving muscle stem cell (satellite cell) function and regenerative capacity (animal: de Keizer, 2017, Cell). Senescent cells in muscle secrete SASP factors (IL-6, IL-1β, MMP-3) that impair neighboring healthy cells and create a pro-inflammatory microenvironment — clearance reverses this. Potential for sarcopenia treatment by removing senescent cells that inhibit muscle regeneration (theoretical, supported by animal data). CARDIOVASCULAR: Senescent endothelial cells and vascular smooth muscle cells contribute to atherosclerosis and vascular stiffening. Senolytic clearance improved vascular function in mouse models (animal: not FOXO4-DRI specifically, but senolytic class data from dasatinib+quercetin studies supports the mechanism). SASP factors drive chronic vascular inflammation — clearance reduces this burden. NEUROLOGICAL: Senescent glial cells (astrocytes, microglia) contribute to neuroinflammation and neurodegeneration. Clearing senescent cells improved cognitive function in tauopathy mouse models (animal: Bussian et al., 2018, Nature). FOXO4-DRI specifically has limited CNS data — BBB penetration of the D-retro-inverso peptide is unclear. ENDOCRINE: Senescent beta-cells in pancreas contribute to age-related glucose intolerance. Senescent thyrocytes impair thyroid function. Clearance could theoretically restore endocrine organ function. IMMUNE: Complex dual effect — senescent immune cells are part of immunosenescence (bad), but the immune system also uses SASP signaling for wound healing and tumor surveillance. FOXO4-DRI-mediated senolysis is selective for senescent cells, theoretically preserving healthy immune function while clearing senescent immune cells. In aged mice, immune function improved after senolytic treatment (animal). GI: Senescent cells accumulate in GI epithelium with age. GI-specific effects of FOXO4-DRI not specifically studied. SKIN: Senescent fibroblasts and keratinocytes are major drivers of skin aging — they secrete MMPs that degrade collagen and elastin. In mice, FOXO4-DRI treatment restored fur density (a measure of dermal health) (animal: de Keizer, 2017). METABOLIC: Senescent adipocytes drive adipose tissue dysfunction, insulin resistance, and chronic inflammation. Senolytic treatment improved metabolic parameters in obese mice (animal: senolytic class data). HEPATIC: Senescent hepatocytes accumulate in NAFLD/NASH and fibrosis. Senolytic clearance reduced liver fibrosis in mouse models (animal: Ogrodnik et al., 2017). RENAL: In the original de Keizer study, aged mice treated with FOXO4-DRI showed restored kidney function (reduced proteinuria, improved glomerular filtration) — one of the most striking findings (animal). REPRODUCTIVE: Senescent cells in ovarian tissue may contribute to reproductive aging. Theoretical application for extending reproductive lifespan. Tier 3: Early adopter practitioners report subjective improvements in energy, skin quality, and joint comfort. Some practitioners monitor senescent cell burden via p16INK4a blood test before and after treatment. Case reports (unpublished) describe improved renal function markers in patients with mild CKD after FOXO4-DRI course. Community reports (Tier 4) describe a "flu-like" phase 3-7 days after starting treatment, interpreted as SASP-release from dying senescent cells — practitioners call this the "senolytic crisis."

Practitioner Guide

DOSING TIPS: NO ESTABLISHED HUMAN DOSE. This is a research peptide with only animal data. Practitioners who use it have extrapolated from the de Keizer mouse data. Common practitioner protocol (empirical, not validated): 2-10mg/kg body weight, administered subcutaneously, for 3 consecutive days, repeated every 2-4 weeks for 2-3 courses. Some use lower doses: 0.5-2mg/kg/day x 5 days. Start at the low end and monitor carefully. This is one of the most expensive peptide protocols due to the large peptide size (requires gram-scale synthesis for reasonable dosing). RECONSTITUTION: Lyophilized powder — reconstitute with bacteriostatic water. Due to the larger peptide size (~4.8 kDa), ensure complete dissolution — may need gentle swirling for 1-2 minutes. Do not vortex aggressively. Typical reconstitution: if 50mg vial, add 2mL BAC water = 25mg/mL. Refrigerate, use within 2-3 weeks. INJECTION SITE: Subcutaneous — abdominal fat pad preferred for consistent absorption. Rotate sites. Volume per injection can be significant due to dosing — split across 2 sites if >2mL. TIMING: Morning administration preferred by most practitioners. Fasted state. Some protocols specify timing relative to exercise (avoid intense exercise for 24-48 hours after dosing to allow senolytic clearance without exercise-induced stress). SUPPLEMENT SYNERGIES: Fisetin (1-2g, flavonoid senolytic) can be taken on treatment days to enhance senolytic activity — the "senolytic cocktail" approach. Quercetin (1g) + dasatinib (prescription) is the other validated senolytic combination (Kirkland group). DO NOT combine FOXO4-DRI with dasatinib+quercetin simultaneously — excessive senolytic load. Support clearance of senescent cell debris: ensure adequate hydration, glutathione/NAC for detoxification support, omega-3s for anti-inflammatory support. After senolytic course: follow with regenerative peptides (BPC-157, GHK-Cu) to support tissue renewal in the spaces cleared of senescent cells. CYCLING: Strict course-based dosing. 3-5 days of treatment, then 4-8 weeks off. Monitor biomarkers between courses. Most practitioners do 2-3 courses per year maximum. The "clear and rebuild" paradigm: senolytic course → 2-4 weeks rest → regenerative peptide course → 4-6 months off. STACKING: Sequential (not simultaneous) stacking: Course 1: FOXO4-DRI (senolytic clearance). Weeks 3-6: BPC-157 + GHK-Cu (tissue regeneration). Months 2-6: Epithalon + NAD+ precursor (cellular maintenance). Some practitioners combine with intermittent fasting (72-hour water fast) which independently activates autophagy and may synergize with senolysis. CONTRAINDICATION NUANCES: ABSOLUTELY AVOID in patients with active cancer — p53 activation is a double-edged sword. While freeing p53 kills senescent cells, it could also affect cancer cell dynamics unpredictably. Avoid in immunosuppressed patients — senolytic clearance requires intact immune function to clean up apoptotic debris. Avoid in patients with active infections — SASP has antimicrobial properties; clearing senescent cells during infection could be harmful. Avoid in patients with impaired wound healing — senescent cells play a transient beneficial role in acute wound repair. Monitor: CBC, CMP, inflammatory markers (CRP, IL-6), kidney function, liver function before and 2-4 weeks after each course. The "senolytic crisis" (flu-like symptoms days 3-7) is expected but should be monitored — if severe, may indicate excessive senescent cell burden and need for slower approach. STORAGE: Lyophilized — store at -20°C for long-term, 4°C for short-term. Reconstituted — refrigerate, use within 2-3 weeks. Protect from light. D-retro-inverso structure provides protease resistance but not indefinite stability. COMPOUNDING: Not available from standard compounding pharmacies. Sourced from research peptide suppliers. Verify purity by HPLC and mass spectrometry — the D-amino acid configuration is critical and must be confirmed. Cost is high ($300-800 per course at typical dosing). PATIENT EDUCATION: This is the most experimental peptide in common use. Explain: no human trials exist, dosing is extrapolated from mice, and long-term effects are unknown. The science (published in Cell) is compelling but early. The "flu-like" phase is expected and actually a positive sign that senolytic clearance is occurring. This is not a maintenance therapy — it is periodic cellular housekeeping. Emphasize the importance of monitoring bloodwork. Tier 4 community intelligence: Early adopters on longevity forums report the clearest subjective benefits in people over 50 with high inflammatory markers at baseline. Reports of improved joint comfort, skin quality, energy, and cognitive clarity 2-4 weeks after completing a course. Cost is the major barrier to widespread adoption.

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No human safety data. Senolytic peptide that induces apoptosis in senescent cells could have catastrophic effects on fetal development, where controlled senescence and apoptosis play critical developmental roles.
  Action: Do not use during pregnancy. Absolutely contraindicated.
• hard stop — Breastfeeding
  No human safety data. Do not use during lactation.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Research compound. Not for pediatric use.
  Action: Do not provide to individuals under 18.
• requires physician — Active chemotherapy
  FOXO4-DRI disrupts the FOXO4-p53 interaction to induce apoptosis in senescent cells. Many chemotherapy regimens rely on inducing senescence in tumor cells as part of their anticancer mechanism. FOXO4-DRI could interfere with this intended therapeutic senescence, potentially clearing tumor cells that are being held in growth arrest by the chemotherapy.
  Action: Requires oncologist evaluation. Do not use concurrently with chemotherapy without explicit oncologist approval. Timing relative to chemotherapy cycles is critical.
• caution — General use
  FOXO4-DRI has NO established human safety profile. It is a research peptide tested only in animal models. The concept of targeted senescent cell clearance is promising but the therapeutic window, off-target effects, and long-term consequences are completely unknown in humans.
  Action: Use only with full informed consent. Medical supervision essential. Monitor blood counts, liver, and kidney function.

Evidence

• Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

  Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourber BRM, Stryber S, Rijksen YMA, van Willigenburg H, Feijtel DA, van der Pluijm I, Essens J, van Cappellen WA, van IJcken WF, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ (2017) — Cell — PMID: 28340339

  FOXO4-DRI, a D-retro-inverso peptide that disrupts the FOXO4-p53 interaction, selectively induced apoptosis in senescent cells in vivo. Treatment of aged mice restored fitness, fur density, and renal function. In fast-aging mice, FOXO4-DRI counteracted chemotherapy-induced senescence and loss of tissue homeostasis. Represents a targeted senolytic approach with selectivity for senescent over non-senescent cells.

  moderate

Research Summary

TIER 1 (Gold Standard): de Keizer et al., 2017 — "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging" (Cell, PMID: 28340339). This is the foundational paper. Demonstrated that FOXO4-DRI selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction, restoring fitness, fur density, and renal function in aged mice. Landmark paper in senolytic field. No human RCTs exist. TIER 2 (Strong): Baker et al., 2016 — genetic clearance of p16-positive senescent cells extends lifespan in mice (Nature, PMID: 26840489 — validates the senolytic hypothesis). Kirkland group — dasatinib + quercetin senolytic combination (Aging Cell, 2015, PMID: 25754370). Xu et al., 2018 — senolytics improve physical function and extend lifespan in old mice (Nature Medicine, PMID: 29988130). Comprehensive reviews: Kirkland & Tchkonia, 2020 (Journal of Internal Medicine). DrugBank: not listed (research compound). TIER 3 (Moderate): Practitioner case series (unpublished) documenting improved renal function, inflammatory markers, and patient-reported outcomes after FOXO4-DRI treatment. Conference presentations at longevity medicine conferences. Biohacking community tracking data on blood biomarkers pre/post treatment. International data: limited to early-adopter clinics in US, Netherlands (de Keizer group affiliation), and some European anti-aging centers. KEY FINDINGS: (1) FOXO4-DRI is the first peptide-based senolytic with a clear, published mechanism. (2) Animal data is compelling — published in one of the highest-impact journals. (3) The senolytic field is rapidly advancing, validating the core hypothesis. (4) NO human safety or efficacy data exists. (5) D-retro-inverso design provides protease resistance, solving a key peptide therapy challenge. GAPS: Human pharmacokinetics entirely unknown. Optimal dosing in humans. Long-term safety (what happens after multiple rounds of senolytic clearance?). Whether clearance of senescent cells is always beneficial (transient senescence plays roles in wound healing, development, and tumor suppression). Biomarker for patient selection (who has enough senescent cell burden to benefit?). ACTIVE TRIALS: No registered trials on ClinicalTrials.gov for FOXO4-DRI specifically. Multiple trials for other senolytics (dasatinib+quercetin, fisetin) are active and informing the field.